Interleukin-1 in Cerebral Ischemia

Access this Article

Search this Article


    • BETZ A Lorris
    • Department of Surgery (Neurosurgery), University of Michigan
    • SCHIELKE Gerald P
    • Department of Neurological and Neurodegenerative Diseases, Parke-Davis Pharmaceutical Research, Division of the Warner-Lambert Company
    • YANG Guo-Yuan
    • Department of Surgery (Neurosurgery), University of Michigan


During the past several years, it has become increasingly apparent that interleukin-1 (IL-1), particularly IL-1β plays an important role in brain injury during ischemia. Studies from various laboratories have shown that IL-1β mRNA and IL-1β protein are synthesized early in ischemia and that the injection of IL-1β into ischemic brain enhances edema formation. The most direct evidence that IL-1β contributes to ischemic injury, however, is the demonstration that infarct volume in focal ischemia is reduced following intraventricular injection of an endogenous interleukin-1 receptor antagonist (IL-1ra), or after IL-lra is overexpressed in brain using an adenoviral vector to transfer IL-Ira cDNA to brain cells. Ischemic injury is also reduced in mice that fail to produce IL-1β because of an abnormal interleukin-1β converting enzyme gene (ICE knockout mice). At the present time, it is unclear how IL-1β causes brain injury, but several possible mechanisms include 1) stimulation of an inflammatory response through the activation of glia or the induction of other cytokines and/or endothelial adhesion molecules and 2) release of free radicals through stimulation of arachidonic acid metabolism and/or nitric oxide synthase activity.


  • Keio J. Med.  

    Keio J. Med. 45(3), 230-238, 1996-09-01 

    The Keio Journal of Medicine

References:  102

You must have a user ID to see the references.If you already have a user ID, please click "Login" to access the info.New users can click "Sign Up" to register for an user ID.


  • NII Article ID (NAID)
  • Text Lang
  • Article Type
  • ISSN
  • Data Source
Page Top